Our top pick for
iCAD Inc is a health information services business based in the US. iCAD shares (ICAD) are listed on the NASDAQ and all prices are listed in US Dollars. iCAD employs 113 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$10.73|
|52-week range||$8.73 - $21.44|
|50-day moving average||$11.25|
|200-day moving average||$15.24|
|Wall St. target price||$24.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.35|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-0.09%|
|1 month (2021-09-16)||3.87%|
|3 months (2021-07-16)||-30.42%|
|6 months (2021-04-16)||-39.69%|
|1 year (2020-10-16)||14.03%|
|2 years (2019-10-16)||58.49%|
|3 years (2018-10-16)||226.14%|
|5 years (2016-10-14)||132.75%|
|Revenue TTM||$34.1 million|
|Gross profit TTM||$21.7 million|
|Return on assets TTM||-8.29%|
|Return on equity TTM||-21.47%|
|Market capitalisation||$268.9 million|
TTM: trailing 12 months
There are currently 855,751 iCAD shares held short by investors – that's known as iCAD's "short interest". This figure is 2.9% down from 881,262 last month.
There are a few different ways that this level of interest in shorting iCAD shares can be evaluated.
iCAD's "short interest ratio" (SIR) is the quantity of iCAD shares currently shorted divided by the average quantity of iCAD shares traded daily (recently around 184429.09482759). iCAD's SIR currently stands at 4.64. In other words for every 100,000 iCAD shares traded daily on the market, roughly 4640 shares are currently held short.
However iCAD's short interest can also be evaluated against the total number of iCAD shares, or, against the total number of tradable iCAD shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case iCAD's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 iCAD shares in existence, roughly 30 shares are currently held short) or 0.0369% of the tradable shares (for every 100,000 tradable iCAD shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against iCAD.
Find out more about how you can short iCAD stock.
We're not expecting iCAD to pay a dividend over the next 12 months.
iCAD's shares were split on a 1:5 basis on 15 August 2012. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your iCAD shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for iCAD shares which in turn could have impacted iCAD's share price.
Over the last 12 months, iCAD's shares have ranged in value from as little as $8.73 up to $21.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while iCAD's is 1.137. This would suggest that iCAD's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.